Abstract 103P
Background
The incidence of colorectal cancer (CRC) in young patients is increasing in recent years. However, the difference of genomic landscape between younger and older patients with CRC are poorly investigated and has never been reported in Chinese population.
Methods
A total of 75 CRC patients were enrolled. All kinds of genetic alterations were analyzed by next-generation sequencing (NGS) with Acornmed panel.
Results
Genomic landscape exhibited notable differences between younger and older CRC groups. APC and PIK3CA alterations were more commonly altered in older tumors (p < 0.05), while SMAD4 mutations tended to occur in younger tumors (p = 0.054). Notably, mutational distributions of KRAS in younger group differed from those in older group, and a higher prevalence of KRAS codon 12 alterations was potentially associated with young age (p = 0.076). Furthermore, the majority of patients (77.3%) harbored at least one clinically actionable alteration, and targeted genetic profiles between younger and older patients were significantly different (p < 0.05). Additionally, in patients with mismatch repair-proficient and mscirosatellite-stable (pMMR/MSS) CRC, tumor mutational burden (TMB) was positively correlated with age (p < 0.05), and a significantly association was found between high TMB and DNA damage response (DDR) pathway alterations (p < 0.05).
Conclusions
This study revealed different molecular profiles between younger and older Chinese patients with CRC, which provided novel insights into the personalized therapy in CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Acornmed Biotechnology Co., Ltd.
Funding
Has not received any funding.
Disclosure
H. Wang, H. Cheng, T. Zhou, F. Lou, S. Cao: Full/Part-time employment: Acornmed Biotechnology Co., Ltd.
Resources from the same session
413P - South Korean real-world treatment patterns in patients with EGFRm NSCLC
Presenter: Jae Cheol Lee
Session: e-Poster Display Session
414P - Incidence and characteristics of lung cancer diagnosed after kidney transplantation at the National Kidney and Transplant Institute
Presenter: Adeline Gonzales
Session: e-Poster Display Session
415P - Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing
Presenter: Chunwei Xu
Session: e-Poster Display Session
416P - A single institute study evaluating the additional benefit of blood NGS testing over conventional molecular testing in metastatic adenocarcinoma lung
Presenter: Rajashree Ashwath
Session: e-Poster Display Session
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
Presenter: Amit Kumar
Session: e-Poster Display Session
418P - All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
Presenter: Ullas Batra
Session: e-Poster Display Session
419P - Surgical treatment of malignant tumours and metastatic lesions of the chest wall
Presenter: Zhanat Pyssanova
Session: e-Poster Display Session
421P - A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Presenter: Ming Gao
Session: e-Poster Display Session
422P - Response rate and time to progression after first line chemotherapy with cisplatin and adriamycin in patients with metastatic osteosarcoma at presentation
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
423P - Positive lymph node and thicker Breslow are associated with poor prognosis of high-risk resected melanomas
Presenter: Roby Cahyono
Session: e-Poster Display Session